GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (OTCPK:TLIS) » Definitions » Financial Strength

TLIS (Talis Biomedical) Financial Strength : 3 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Financial Strength?

Talis Biomedical has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

GuruFocus does not calculate Talis Biomedical's interest coverage with the available data. As of today, Talis Biomedical's Altman Z-Score is -12.15.


Competitive Comparison of Talis Biomedical's Financial Strength

For the Medical Devices subindustry, Talis Biomedical's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talis Biomedical's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Financial Strength distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Financial Strength falls into.


;
;

Talis Biomedical Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Talis Biomedical's Interest Expense for the months ended in Jun. 2024 was $0.00 Mil. Its Operating Income for the months ended in Jun. 2024 was $-9.58 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $15.88 Mil.

Talis Biomedical's Interest Coverage for the quarter that ended in Jun. 2024 is

GuruFocus does not calculate Talis Biomedical's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Talis Biomedical Corp has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Talis Biomedical's Debt to Revenue Ratio for the quarter that ended in Jun. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.923 + 15.877) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Talis Biomedical has a Z-score of -12.15, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -12.15 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talis Biomedical  (OTCPK:TLIS) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Talis Biomedical has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Talis Biomedical Financial Strength Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Talis Biomedical Business Description

Traded in Other Exchanges
N/A
Address
1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Executives
Andrew A Lukowiak officer: President, other: Chief Scientific Officer 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich officer: Interim CFO CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser director, officer: President and CEO 561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan officer: Sr. Vice President, R&D 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Moody John Roger Jr officer: Chief Financial Officer 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062